296 related articles for article (PubMed ID: 22985581)
21. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium.
Salmi A; Pakarinen P; Peltola AM; Rutanen EM
Mol Hum Reprod; 1998 Dec; 4(12):1110-5. PubMed ID: 9872360
[TBL] [Abstract][Full Text] [Related]
22. [Effect of levonorgestrel intrauterine device on human endometrial estrogen and progesterone receptors].
Lu SM
Zhonghua Fu Chan Ke Za Zhi; 1991 Sep; 26(5):293-4, 323. PubMed ID: 1935411
[TBL] [Abstract][Full Text] [Related]
23. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
24. Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel-releasing intrauterine system.
Möller B; Rönnerdag M; Wang G; Odlind V; Olovsson M
Hum Reprod; 2005 May; 20(5):1410-7. PubMed ID: 15760960
[TBL] [Abstract][Full Text] [Related]
25. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
26. Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel.
Hurskainen R; Salmi A; Paavonen J; Teperi J; Rutanen E
Mol Hum Reprod; 2000 Nov; 6(11):1013-8. PubMed ID: 11044464
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a levonorgestrel-releasing intrauterine system for treating endometrial hyperplasia in patients with polycystic ovary syndrome.
Lin M; Xu X; Wang Y; Hu Y; Zhao Y
Gynecol Obstet Invest; 2014; 78(1):41-4. PubMed ID: 24852134
[TBL] [Abstract][Full Text] [Related]
28. Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium.
Burton KA; Henderson TA; Hillier SG; Mason JI; Habib F; Brenner RM; Critchley HO
Hum Reprod; 2003 Dec; 18(12):2610-7. PubMed ID: 14645180
[TBL] [Abstract][Full Text] [Related]
29. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
Haoula ZJ; Walker KF; Powell MC
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
[TBL] [Abstract][Full Text] [Related]
30. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system.
Ercan CM; Duru NK; Sakinci M; Alanbay I; Karasahin KE; Baser I
Gynecol Endocrinol; 2010 Feb; 26(2):125-8. PubMed ID: 20074021
[TBL] [Abstract][Full Text] [Related]
31. Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy.
Wildemeersch D; Schacht E; Wildemeersch P; Calleweart K; Pylyser K; De Wever N
Maturitas; 2004 May; 48(1):65-70. PubMed ID: 15223110
[TBL] [Abstract][Full Text] [Related]
32. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy.
Varila E; Wahlström T; Rauramo I
Fertil Steril; 2001 Nov; 76(5):969-73. PubMed ID: 11704119
[TBL] [Abstract][Full Text] [Related]
33. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
[TBL] [Abstract][Full Text] [Related]
34. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study.
Heikinheimo O; Vani S; Carpén O; Tapper A; Härkki P; Rutanen EM; Critchley H
Hum Reprod; 2007 Sep; 22(9):2515-22. PubMed ID: 17636280
[TBL] [Abstract][Full Text] [Related]
35. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
Ewies AA; Alfhaily F
Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
[TBL] [Abstract][Full Text] [Related]
36. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
[TBL] [Abstract][Full Text] [Related]
37. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.
Varma R; Sinha D; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):9-28. PubMed ID: 16325993
[TBL] [Abstract][Full Text] [Related]
38. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
39. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
[TBL] [Abstract][Full Text] [Related]
40. PROgesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study.
Derbyshire AE; Allen JL; Gittins M; Lakhiani B; Bolton J; Shaw J; Pemberton PW; Needham M; MacKintosh ML; Edmondson RJ; Kitchener HC; Crosbie EJ
Cancer Prev Res (Phila); 2021 Feb; 14(2):263-274. PubMed ID: 32998940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
